Publications by authors named "Maria Chiara Valentino"
Article Synopsis
- The study looks at how different types of medications, called biological drugs and biosimilars, affect health care costs for patients with certain diseases, especially in rheumatology.
- Researchers examined 145 patients and found that most were using the original biological drugs instead of the biosimilars, even though patients using biosimilars showed better adherence to treatment.
- The total health costs for these patients over one year was quite high, with a large portion going toward medications, and the study suggests that better communication among health professionals could help more people use biosimilars.
Background: To date, no study evaluated the cost-effectiveness of palbociclib (PAL) plus fulvestrant (FUL) vs ribociclib (RIB) plus FUL and abemaciclib (ABM) plus FUL in Italy. Cost-effectiveness analysis comparing the three cyclin-dependent 4/6 kinase inhibitors in combination with endocrine therapies for the management of postmenopausal women with HR+, HER2- advanced or metastatic breast cancer in Italy was developed.
Material And Methods: To assess the cost-effectiveness of PAL plus FUL vs RIB plus FUL and ABM plus FUL, a cost-minimization has been carried out with a conservative scenario considering three CDK4/6 inhibitors with equal effectiveness in terms of overall survival (OS) (MAIC, Rugo et al 2021).
Background: Aim of our study is to evaluate the economic impact of NASH among diabetic population in Italy and potential benefits of treatments that can slow the disease progression.
Methods: A Markov model was conducted from the Italian National Healthcare System perspective reporting results at 3, 5, 10 and 15 years. The model included NASH and T2DM patients with all stages of fibrosis (F0-F3), compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), liver transplant (LT), post-LT and death.
Aim: To evaluate if VSL#3 [a high-concentration multi-strain probiotic mix containing one strain of BT01, three strains of ( BB02; subspecies [subsp.] BL03, previously identified as BL03; and subsp. BI04, previously identified as BI04), and four strains of ( BA05, BP06, BP07, and BD08, previously identified as subsp.
View Article and Find Full Text PDFBackground: In Italy, the adoption of a total lockdown has generated almost total suspension of outpatient visits except for emergencies. Even after lockdown, the pandemic fear created additional barriers to access the health services. The aim of our study is to evaluate the economic impact of the lockdown for COVID-19 on public health in Italy, focusing on its effects on diabetic population.
View Article and Find Full Text PDFArticle Synopsis
- The study examined the impact of Vitamin D3 on glyco-metabolic control in type 2 diabetic patients who are Vitamin D deficient, with 117 patients in the placebo group and 122 in the Vitamin D3 group.
- After 6 months, the Vitamin D3 group showed significant improvements in fasting and post-prandial glucose levels, as well as a reduction in HbA1c levels compared to both their baseline and the placebo group.
- Patients receiving Vitamin D3 also required lower doses of oral hypoglycemic agents and insulin, suggesting improved diabetes management from Vitamin D3 supplementation.
Diabetes treatment cost represents an ever-growing problem. The adoption of new drugs in therapy, although they can guarantee an improvement in patient's quality of life, can meet obstacles when it involves an increase in costs. We decided to compare the costs and benefits of the new saxagliptin and dapagliflozin combination versus traditional therapies.
View Article and Find Full Text PDFArticle Synopsis
- Diabetes is a global public health issue, leading to serious complications and increased treatment costs, prompting a study on the economic impact of dulaglutide as a diabetes treatment alternative.
- The study utilized a cost-utility analysis to compare the total costs of dulaglutide versus gliclazide (a sulfonylurea) and basal insulin, with a focus on their effectiveness alongside metformin in type II diabetic patients.
- Results indicated that while dulaglutide is more expensive upfront than gliclazide and basal insulin, it may lead to lower overall costs in terms of self-monitoring and hypoglycemia-related expenses.
Article Synopsis
- Asthma is a chronic inflammatory disease affecting quality of life, and the Asthma Quality of Life Questionnaire (AQLQ) is a key tool for measuring patient-reported outcomes (PROs).
- A systematic review was conducted following PRISMA guidelines to assess long-term QoL outcomes related to omalizumab therapy in patients with moderate-to-severe allergic asthma, reviewing studies published until February 2018.
- Results from eight selected studies highlighted that omalizumab significantly improves both subjective and objective measures of asthma control over time, although the observational nature of these studies may introduce selection bias concerns.
Background: Diabetes represents a relevant public health problem worldwide due to its increasing prevalence and socioeconomic burden. There is no doubt that tight glycemic control reduces the development of diabetic complications such as the long-term costs related to the disease. The aim of our model was to calculate total direct costs associated with the two treatments considered in DUAL VII study, and hence evaluate the potential economic benefits for the National Health System (NHS) deriving from the use of insulin degludec plus liraglutide (IDegLira) in a once-daily fixed combination.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on the economic impact of Clostridium difficile infection (CDI) in Italy, particularly in the Florence health care system, highlighting the lack of research on the economic costs associated with CDI.
- It involved a retrospective analysis of 69 patients hospitalized with CDI in 2013, revealing an average hospitalization duration of 12.8 days and a significant average cost of €3,270.52 per patient.
- The findings indicate that prolonged hospital stays contribute the most to these costs, emphasizing the need for better diagnostic and treatment strategies to manage CDI effectively.